1,5-anhydroglucitol is a good predictor for the treatment effect of the Sodium-Glucose cotransporter 2 inhibitor in Japanese patients with type 2 diabetes mellitus
Background and Aims: The suitable selection of appropriate medicines is one of important factor in successful diabetes care. We looked for clinical indicators that could predict the effects of SGLT2 inhibitors in advance. Methods and Results: In a single-center, this retrospective study was designed...
Main Authors: | Masahiro Usui, Mamiko Tanaka, Hironori Takahashi |
---|---|
Format: | Article |
Language: | English |
Published: |
Elsevier
2020-09-01
|
Series: | Journal of Clinical & Translational Endocrinology |
Subjects: | |
Online Access: | http://www.sciencedirect.com/science/article/pii/S2214623720300867 |
Similar Items
-
Pemeriksaan 1,5-Anhydroglucitol, Suatu Hal Baru dalam Pemeriksaan Prediabetes
by: Reza Febryan
Published: (2024-03-01) -
Value of serum 1,5-anhydroglucitol measurements in childhood obesity in the continuum of diabetes
by: Ha Yeong Yoo, et al.
Published: (2015-12-01) -
The clinical potential of 1,5-anhydroglucitol as biomarker in diabetes mellitus
by: Haiying Xu, et al.
Published: (2024-10-01) -
Evaluation of 1,5-Anhydroglucitol as a Biomarker for Type 2 Diabetes Mellitus in Patients without Overt Nephropathy
by: Luiza Cristina Gobor, et al.
Published: (2021-10-01) -
Sotagliflozin, an inhibitor of sodium–glucose cotransporters 1 and 2 (SGLT1/2), as a new therapeutic approach for patients with type 1 diabetes mellitus
by: Mirella Czapska, et al.
Published: (2018-12-01)